Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CASP2 | P42575 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272809 | 0.82 | SIGMAR1 (0.49) | CACNA1HALDH1A1RECQLSIGMAR1CASP2 | |
| SCHEMBL24535555 | 0.80 | SIGMAR1 (0.40) | CACNA1HALDH1A1RECQLSIGMAR1CASP2 | |
| SCHEMBL19115237 | 0.80 | MAPT (0.45) | CACNA1HALDH1A1TSHR | |
| SCHEMBL21579953 | 0.79 | EPHX1 (0.34) | TP53BP1 | |
| SCHEMBL18738817 | 0.79 | KDM4C (0.46) | ALDH1A1CASP2 | |
| SCHEMBL14176518 | 0.79 | CASP2 (0.44) | ALDH1A1RECQLCASP2TSHRTP53BP1 | |
| SCHEMBL20261178 | 0.78 | DPP4 (0.37) | CACNA1HRECQL | |
| SCHEMBL8070389 | 0.78 | LDHA (0.34) | CACNA1HALDH1A1RECQLCASP2TSHR | |
| SCHEMBL25083240 | 0.78 | CASP2 (0.52) | ALDH1A1CASP2 | |
| SCHEMBL13853869 | 0.78 | KEAP1 (0.36) | CACNA1HALDH1A1RECQLCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | CD74, CD2BP2, SERPINB1 | CACNA1H 3067/4885ALDH1A1 3301/4885RECQL 4411/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | CACNA1H 2991/4885ALDH1A1 2795/4885RECQL 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.